

PUBLISHED VERSION

Cleland, Leslie Glen; James, Michael John
[COX-2 selectivity varies across class](#) Medical Journal of Australia, 2005; 182
(4):197-198

This article is available from the Medical Journal of Australia at:

http://www.mja.com.au/public/issues/182_04_210205/matters_arising_210205_fm-2.html

PERMISSIONS

This document has been archived with permission from the editor of the Medical Journal of Australia, 26 April 2007.

<http://hdl.handle.net/2440/33166>

MATTERS ARISING

- 197 **Withdraw all COX-2-selective drugs**
Peter R Mansfield, Agnès I Vitry, James M Wright
- 197 **COX-2 selectivity varies across class**
Leslie G Cleland, Michael J James
- 198 **Possible genetic predisposition to cardiac effects**
Hari Manev, Radmila M Manev
- 198 **Paracetamol should be first-line therapy in osteoarthritis**
Richard O Day, Garry G Graham
- 199 **Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions**
Paul Langton, Graeme Hankey, John Eikelboom

LETTER

- 200 **Acute presentation of childhood hypothyroidism**
Ursula Bayliss, Christopher Cowell, James Hong,
Veronica Wiley, Bridget Wicken

Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions

A recent editorial on the safety and recent withdrawal of rofecoxib has stimulated a number of letters (Med J Aust 2004; 181: 524-525)

Withdraw all COX-2-selective drugs

Peter R Mansfield,* Agnès I Vitry,† James M Wright‡

* Research Fellow, Department of General Practice, University of Adelaide, 34 Methodist Street, Willunga, SA 5172; † Senior Lecturer, QUMPPRC, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide; ‡ Professor, Department of Pharmacology & Therapeutics and Medicine, University of British Columbia, Vancouver, BC, Canada. peter.mansfield@adelaide.edu.au

TO THE EDITOR: Langton et al claim that “the celecoxib studies have not demonstrated an increased risk of thrombosis”.¹ However, the European Agency for the Evaluation of Medicinal Products concluded that “there is a trend towards a higher MI [myocardial infarction] risk associated with the use of celecoxib compared with naproxen and diclofenac”, and decided that a warning statement was required for all cyclooxygenase 2 (COX-2)-selective drugs.² It is surprising that celecoxib may be worse than diclofenac, because diclofenac is similarly COX-2-selective as celecoxib.^{3,4}

A retrospective analysis of the full CLASS study data for people not taking aspirin found the rates of serious thromboembolic cardiovascular events were celecoxib 1.4% and diclofenac 1.6%, as against 0.7% for ibuprofen.⁵ These differences were not individually statistically significant, but CLASS was underpowered for cardiovascular events. However, pooling the results for the two similarly COX-2-selective drugs versus ibuprofen reveals a significant difference (relative risk [RR], 2.1; 95% CI, 1.1–3.9). In the full CLASS data, celecoxib did not have a lower rate of complicated ulcers (RR, 0.83; 95% CI, 0.46–1.5) and there was a trend towards more serious adverse events of all types (RR, 1.17; 95% CI, 0.99–1.39) than in the combined ibuprofen and diclofenac groups.^{3,6}

We conclude that the case against all COX-2-selective drugs has not been proven beyond doubt because they have not been studied adequately. However, on the balance of probabilities, they are all likely to have a similar propensity to rofecoxib to increase thrombotic cardiovascular events to some extent. This prothrombotic effect may be reduced by combining them with aspirin,

but then the main gastrointestinal benefit is likely to be lost,^{3,4} so use of such combinations is not justified.

Overall, celecoxib is no more effective, more expensive, no safer (and possibly less safe) than non-selective drugs. Meloxicam has not been shown to be any better. COX-2-selective drugs should not be used unless a subpopulation can be identified for whom these drugs have an advantage over the non-selective drugs. In theory, COX-2-selective drugs may be useful for a tiny group of people who are at greater risk of serious harm from gastrointestinal injury than from vascular events. However, there is no proven way to identify such people and there are no relevant trials to guide us. For example, no trials have been done in patients with a history of peptic ulcer.

All COX-2-selective drugs should be removed from the market until they have been properly evaluated.

1 Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions [editorial]. *Med J Aust* 2004; 181: 524-525. Previously published online, 26 October 2004.

2 Celecoxib. Annex II: Overall summary of the scientific evaluation of medicinal products containing celecoxib, etoricoxib, parecoxib, rofecoxib, or valdecoxib. London: European Agency for the Evaluation of Medicinal Products, 2004. Available at: www.emea.eu.int/pdfs/human/referral/celecoxib/EN%20Celecoxib.pdf (accessed Nov 2004).

3 Wright JM. The double-edged sword of COX-2 selective NSAIDs. *Can Med Assoc J* 2002; 167: 1131-1137.

4 Fitzgerald GA. Coxibs and cardiovascular disease. *N Engl J Med* 2004; 351: 1709-1711.

5 Strand V, Hochberg MC. The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. *Arthritis Rheum* 2002; 47: 349-355.

6 Bassett K, Wright JM, Puil L, et al. Cyclooxygenase-2 inhibitor update: journal articles fail to tell the full story. *Can Fam Physician* 2002; 48: 1455-1460. □

COX-2 selectivity varies across class

Leslie G Cleland,* Michael J James†

* Director, † Chief Medical Scientist, Department of Rheumatology, Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000
lcleland@mail.rah.sa.gov.au

TO THE EDITOR: Langton et al document the history of rofecoxib approval in 1999 and withdrawal in 2004.¹ They also provide

an outline of the possible mechanisms for increased cardiovascular risk, which we detailed in the Journal in August 2001.² Their editorial raises the issue of whether the increased cardiovascular risk is a class effect of all selective cyclooxygenase 2 (COX-2) inhibitors and notes that no increased risk has been identified to date with celecoxib use. While this is correct, the editorial omits to state that, although several drugs are categorised as “COX-2 inhibitors”, the selectivity for COX-2 over COX-1 inhibition varies greatly between different drugs (see Box).³

Selectivity for COX-2 for different “COX-2 inhibitors”³

Drug	COX-1/COX-2 (IC ₅₀ ratio)
Aspirin	<0.5
Ibuprofen	0.5
Meloxicam	18
Diclofenac	29
Celecoxib	30
Rofecoxib	267

It is potentially significant that celecoxib is only modestly COX-2 selective compared with rofecoxib. Because COX-2-selective inhibition can lead to selective inhibition of vascular prostacyclin synthesis with little or no effect on vascular or platelet thromboxane synthesis,¹ a highly selective COX-2 inhibitor such as rofecoxib is expected to disrupt the balance between antithrombotic prostacyclin and prothrombotic thromboxane. The relatively modest COX-2 selectivity of celecoxib may be one explanation for the lack of adverse cardiovascular effects demonstrated to date. It would also explain its lack of upper gastrointestinal tract protection relative to diclofenac, as both drugs have similar COX-2 selectivity.⁴

The newer coxibs, like rofecoxib, are significantly more COX-2-selective than celecoxib and, if this selectivity is the basis for the adverse cardiovascular events, then caution is needed with these newer agents. Although the editorial states that trials have not shown increased risk with the newer coxibs, this is not correct. On 15 October 2004, Pfizer announced that valdecoxib, when used for pain management in coro-

nary artery bypass surgery, caused an increased number of adverse cardiovascular events.⁵

As the editorial states, the VIGOR study with rofecoxib in treating rheumatoid arthritis revealed a greatly increased incidence of adverse cardiovascular events compared with naproxen, and yet rofecoxib sales continued for another four years at a high level.¹ Perhaps the most important question for prescribers arising from the experience with rofecoxib is not whether clinical trial results are conclusive, but how should prescribers respond to apparent conflicts in the medical literature. In such a situation, resort to ethical and legal obligations for disclosure of information will be the prudent approach, as we have detailed.⁶

For prescribers considering the loss of rofecoxib, some perspective is provided by the following. The number needed to treat (NNT) to cause an increase in one fatal or non-fatal cardiac event in the VIGOR study was 225 (average trial duration was 9 months). In trials with statins in which coronary heart disease was absent at enrolment, the NNT per year to prevent one fatal or non-fatal coronary event was 217 to 256.⁷

1 Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions [editorial]. *Med J Aust* 2004; 181: 524-525. Previously published online, 26 October 2004.

2 Cleland LG, James MJ, Stamp LK, Penglis PS. COX-2 inhibition and thrombotic tendency: a need for surveillance. *Med J Aust* 2001; 175: 214-217.

3 Patrono C, Patrignani P, Garcia-Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. *J Clin Invest* 2001; 108: 7-13.

4 Juni P, Rutjes AWS, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? *BMJ* 2002; 324: 1287-1288.

5 Pfizer provides information to healthcare professionals about its Cox-2 medicine Bextra® (Valdecoxib) [press release]. 15 October 2004. Available at: www.pfizer.com/are/news_releases/2004pr/mn_2004_1015.html (accessed Nov 2004).

6 James MJ, Cleland LG. Applying a research ethics committee approach to a medical practice controversy: the case of COX-2 inhibitors. *J Med Ethics* 2004; 30: 182-184.

7 Kumana CR, Cheung BM, Lauder IJ. Gauging the impact of statins using number needed to treat. *JAMA* 1999; 282: 1899-1901. □

Possible genetic predisposition to cardiac effects

Hari Manev,* Radmila M Manev†

* Professor, † Assistant Professor of Clinical Psychiatry, Department of Psychiatry, University of Illinois at Chicago, 1601 West Taylor Street, MC912, Chicago, Illinois, 60612, USA
hmanev@psych.uic.edu

TO THE EDITOR: In their editorial on the rofecoxib controversy, Langton et al point out that large-scale but inconclusive studies failed to recognise an increased risk of heart attack and stroke in patients treated with this cyclooxygenase 2 (COX-2) inhibitor.¹ Might something still be learned from these studies? Both COX-2 and 5-lipoxygenase (5-LOX) use the same substrate (arachidonic acid) to produce prostaglandins and leukotrienes, respectively. Overactive 5-LOX increases the risk of heart attack and stroke,^{2,3} and may be involved in the comorbidity of these disorders with anxiety and depression.⁴ In contrast, COX-2 appears to be cardioprotective.⁵

Genetic diversity is responsible for overactive 5-LOX in some individuals and increases their risk for cardiovascular pathology.^{2,3} It is likely that patients with these alleles might be more susceptible to cardiovascular pathology in the absence of COX-2 activity — that is, be at increased risk of rofecoxib-provoked myocardial infarction and stroke.

If possible, retrospective studies should be attempted to determine the genotype of subjects treated with rofecoxib for 5-LOX² and 5-LOX-activating protein³ polymorphisms and to relate these findings to rates of myocardial infarction and stroke.

1 Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions [editorial]. *Med J Aust* 2004; 181: 524-525. Previously published online, 26 October 2004.

2 Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. *N Engl J Med* 2004; 350: 29-37.

3 Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. *Nat Genet* 2004; 36: 233-239.

4 Manev R, Manev H. 5-Lipoxygenase as a putative link between cardiovascular and psychiatric disorders. *Crit Rev Neurobiol* 2004; 16: 177-182.

5 FitzGerald GA. Coxibs and cardiovascular disease. *N Engl J Med* 2004; 351: 1709-1711. □

Paracetamol should be first-line therapy in osteoarthritis

Richard O Day,* Garry G Graham†

* Professor of Clinical Pharmacology, University of New South Wales and St Vincent's Hospital, Victoria Road, Darlinghurst, NSW 2010; † Emeritus Professor of Pharmacology, University of New South Wales, Sydney, NSW
r.day@unsw.edu.au

TO THE EDITOR: We consider that it is important to comment on the views expressed by Langton et al on the limited value of paracetamol in the treatment of musculoskeletal pain.¹

Langton et al recognise that paracetamol is widely recommended as first-line therapy to reduce chronic pain, but they largely dismiss its usefulness, noting that:

... when used alone paracetamol appears to be less effective than NSAIDs and there are no studies of the safety of the long-term intake of paracetamol.¹

However, paracetamol is widely recommended as the first-line drug treatment in the management of osteoarthritis. This is based on its efficacy and safety as compared with nonsteroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase 2 (COX-2) inhibitors. This position is supported by published guidelines, including those of the American College of Rheumatology² and the European League of Associations of Rheumatology (EULAR).³ In these guidelines, NSAIDs are recommended for use in moderate to severe osteoarthritis pain (American College of Rheumatology guidelines) or where the pain is unresponsive to paracetamol (EULAR guidelines). Our own Australian Therapeutic Guideline series and National Prescribing Service publications similarly recommend paracetamol as first-line treatment in osteoarthritis⁴ (see National Prescribing Service, Fact Sheet 8, October 2004 <www.nps.org.au>).

The efficacy of paracetamol in comparison with NSAIDs in patients with osteoarthritis has been demonstrated in patients treated for periods ranging from 3 weeks to 2 years, with total daily doses of paracetamol ranging from 2.6 g to 4.0 g,⁵ but this has been contentious.^{6,7} In a 2-year study involving 66 patients with osteoarthritis, Williams et al noted a higher withdrawal rate due to side effects in the naproxen group than in the paracetamol group, and slightly less efficacy in the paracetamol group.⁵ Pincus and colleagues reported that a third of patients receiving paracetamol continued on this treatment for more than 24 months, and

that paracetamol was significantly less likely to be discontinued because of toxicity than NSAIDs.⁸ Thus, although paracetamol is on average less effective in pain reduction compared with NSAIDs,⁶ the difference in efficacy is small and a substantial proportion of patients can be treated satisfactorily and safely with paracetamol alone.⁹

Paracetamol remains the appropriate initial treatment for the management of osteoarthritis. Other medications, such as NSAIDs or COX-2 inhibitors, can be added if patient response is unsatisfactory and the risk-benefit ratios are acceptable. When considering alternative options to rofecoxib, prescribers should also review the non-drug options, such as weight loss, physiotherapy, orthotics, and, where possible, opt for paracetamol first.¹⁰ Prescribers need to continue to be mindful of the potential for adverse effects with NSAIDs, particularly in high-risk patients or patients taking concomitant medications.

The serious public health problem of upper gastrointestinal tract bleeding caused by NSAIDs is a major consideration in the management of patients with osteoarthritis and becomes more of an issue in the elderly, many of whom have osteoarthritis.

Competing interests: Professor Day is a member of advisory committees on COX-2 inhibitors for Merck Sharp & Dohme (Aust) Pty Ltd (which markets rofecoxib and etoricoxib), and previously for Pfizer Pty Ltd (which markets celecoxib). He is a member of a general advisory committee of Glaxo-SmithKline (which markets paracetamol). Glaxo-SmithKline have supported research projects of Professor Graham on paracetamol.

- Langton PE, Hankey GJ, Eikelboom JW. Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions [editorial]. *Med J Aust* 2004; 181: 524-525. Previously published online, 26 October 2004.
- American College of Rheumatology Subcommittee on Osteoarthritis. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. *Arthritis Rheum* 2000; 43: 1905-1915.
- Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCI-SIT). *Ann Rheum Dis* 2003; 62: 1145-1155.
- Musculoskeletal pain. In: Therapeutic guidelines. Analgesic. Version 4, 2002; 133.
- Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. *Arthritis Rheum* 1993; 36: 1196-1206.
- Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. *Arch Intern Med* 2003; 163: 169-178.
- Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. *JAMA* 2002; 287: 64-71.

- Pincus T, Swearingen C, Cummins P, Callahan LF. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. *J Rheumatol* 2000; 27: 1020-1027.
- Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. *Ann Rheum Dis* 2004; 63: 901-907.
- Day RO, Graham GG. The vascular effects of COX-2 selective inhibitors. *Aust Prescr* 2004; 27: 142-145. □

Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions

Paul Langton,* Graeme Hankey,†
John Eikelboom‡

* Cardiologist, Hollywood Private Hospital, Nedlands, WA; † Neurologist, Stroke Unit, ‡ Haematologist, Royal Perth Hospital, GPO Box X2213, Perth, WA 6847
john.eikelboom@health.wa.gov.au

IN REPLY: Mansfield, Vitry and Wright take issue with our statement that the celecoxib studies have not shown an increased risk of thrombosis, but provide no data to support their claims, while Cleland and James highlight differences in COX-2 selectivity as a potential explanation for differences in the cardiovascular safety of coxibs. Recently published clinical data confirm an increased risk of cardiovascular events with rofecoxib but not celecoxib,¹ which is consistent with in-vivo studies suggesting that celecoxib but not rofecoxib improves endothelial function,^{2,3} as well as a significantly lower incidence of oedema and hypertension with celecoxib compared with rofecoxib.⁴ Nevertheless, we reiterate that it remains incumbent on drug manufacturers and regulatory authorities to demonstrate cardiovascular safety for all new and existing coxibs, including celecoxib.

The published coronary artery bypass graft surgery randomised trial referred to by Cleland and James did not report a significant excess of adverse cardiovascular events with valdecoxib,⁵ nor did two recently published meta-analyses.^{6,7} However, unpublished data from a second coronary artery bypass graft surgery trial, as well as meta-analyses presented at the American Heart Association meeting in New Orleans in November 2004, indicate that valdecoxib compared with placebo significantly increases the risk of adverse cardiovascular events.⁸ This is reflected in the recently revised US prescribing information for valdecoxib.⁹

Manev and Manev propose enhanced 5-lipoxygenase activity as a mechanism for increased cardiovascular risk in patients treated with COX-2-selective inhibitors. We agree that this important hypothesis merits further study.

Day and Graham emphasise paracetamol as first-line drug treatment in the management of osteoarthritis, referring to recently published American, European and Australian guidelines to support their position. We do not dispute the effectiveness of paracetamol to reduce chronic pain. However, data from the 2004 systematic review quoted in our editorial¹⁰ demonstrate that nonsteroidal anti-inflammatory drugs are better than paracetamol for pain relief and are often preferred by patients, despite a higher incidence of adverse effects. Only one of the 10 randomised controlled trials included in this systematic review followed patients beyond 3 months; this study reported the primary efficacy outcome only during the first 6 weeks and was not powered for safety.

- Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of non-fatal myocardial infarction. *Ann Intern Med* 2005; 142. Published online 7 Dec 2004. Available at: www.annals.org (accessed Dec 2004).
- Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. *Circulation* 2003; 107: 405-409.
- Bogaty P, Brophy JM, Noel M, et al. Impact of prolonged cyclo-oxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein. A randomised placebo-controlled study. *Circulation* 2004; 110: 934-939.
- Whelton A. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. *J Hypertens* 2002; 20 Suppl 6: S31-S35.
- Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. *J Thorac Cardiovasc Surg* 2003; 125: 1481-1492.
- Edwards JE, McQuay HJ, Moore RA. Efficacy and safety of Valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. *Pain* 2004; 111: 286-296.
- White WB, Strand V, Roberts R, Whelton A. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. *Am J Ther* 2004; 11: 244-250.
- Battling Bextra. Meta-analyses could be taken up at February COX-2 advisory committee. Available at: www.fdaadvisorycommittee.com/FDC/Advisory-Committee/Committees/Arthritis+Drugs/021605_cox2day1/0216-1705_Bextra.htm (accessed Dec 2004).
- New US prescribing information for valdecoxib. Available at: www.pfizer.com/download/uspi_bextra.pdf (accessed Dec 2004).
- Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. *Ann Rheum Dis* 2004; 63: 901-907. □

Acute presentation of childhood hypothyroidism

Ursula Bayliss,* Christopher Cowell,[†]
James Hong,[‡] Veronica Wiley,[§]
Bridget Wicken[¶]

*Clinical Nurse Consultant, §Principal Scientist,
¶Clinical Director, NSW Newborn Screening Programme,
†Head, Institute of Endocrinology & Diabetes, The Children's Hospital at Westmead,
Westmead, NSW 2145; ‡Paediatrician, North Gosford Medical Centre,
North Gosford, NSW.
bridgetw@chw.edu.au

TO THE EDITOR: We report an acute presentation of congenital hypothyroidism in a child almost 6 years old. The condition was not detected by newborn screening.

Screening of all neonates started in New South Wales in July 1977, with thyroid stimulating hormone (TSH) being measured in dried blood spots taken from a heel-prick blood sample (currently at 2–3 days of age). A whole-blood TSH level of 40 mIU/L or above triggers a request for full thyroid function testing, whereas with a level of 20–39 mIU/L a second sample is requested. We have screened over 2.3 million babies and detected 690 babies with congenital hypothyroidism. Ten babies with dysmorphogenesis or ectopic thyroid tissue had normal results and were missed by the screening test. Since screening started, “juvenile hypothyroidism” not associated with thyroid antibodies has all but disappeared.

A healthy girl aged 5 years 11 months presented with acute dysphagia and drooling. There were no previous dysphagic symptoms. Initially, epiglottitis was suspected; however, at endoscopy a lingual thyroid was visualised at the base of her tongue, and this was confirmed by a technetium scan. She had normal growth and development, with both height and weight at the 50th centiles, a pulse rate of 90 beats/min, and normal deep tendon reflexes.

The whole-blood TSH level at newborn screening on Day 3 was 40 mIU/L (reference range [RR], <20 mIU/L). Thyroid function testing at another hospital on Day 10 showed a serum TSH level of 16.6 mIU/L and a serum free thyroxine (FT₄) level within the normal range (12 pmol/L; RR, 11–30 pmol/L). These results were interpreted as normal, whereas, in fact, the TSH level was above the reference range for 10 days of age (<10 mIU/L), although within the reference range for 2–7 days.

On the patient's admission for treatment of acute dysphagia, the TSH level was 10.9 mIU/L and the FT₄ level was 18 pmol/L.

A diagnosis was made of compensated hypothyroidism secondary to the ectopically placed lingual thyroid. Thyroxine treatment was commenced on diagnosis, and regular follow-up arranged. Three months after the start of treatment, the results of thyroid function tests (FT₄, 17 pmol/L; TSH, 2.7 mIU/L) were within the normal range.

Acute presentation of a lingual thyroid is most unusual.¹ This case emphasises that further investigations must be performed when thyroid function test results are equivocal. Unfortunately, the thyroid status was considered normal because the FT₄ value was within the normal range. All babies whose TSH results remain elevated while the FT₄ levels are normal should have a thyroid scan, as we recommend when reporting results.

1 Koch CA, Picken C, Clement SC, et al. Ectopic lingual thyroid: an otolaryngologic emergency beyond childhood. *Thyroid* 2000; 10: 511-514. □

Editor

Martin Van Der Weyden, MD, FRACP, FRCPA

Deputy Editors

Bronwyn Gaut, MBBS, DCH, DA

Ruth Armstrong, BMed

Mabel Chew, MBBS(Hons), FRACGP, FACHPM

Ann Gregory, MBBS, GradCertPopHealth

Manager, Communications Development

Craig Bingham, BA(Hons), DipEd

Senior Assistant Editor

Helen Randall, BSc, DipOT

Assistant Editors

Elsina Meyer, BSc

Kerrie Lawson, BSc(Hons), PhD, MASM

Tim Badgery-Parker, BSc(Hons), ELS

Josephine Wall, BA, BAppSci, GradDipLib

Proof Readers

Richard Bellamy; Christine Binskin, BSc; Sara Thomas, BSc

Editorial Administrator

Kerrie Harding

Editorial Assistant

Christine Hooper

Production Manager

Glenn Carter

Production Assistant

Peter Humphries

Librarian, Book Review Editor

Joanne Elliot, BA, GradDipLib

Consultant Biostatistician

Val GebSKI, BA, MStat

Content Review Committee: Leon Bach, PhD,

FRACP; Adrian Bauman, PhD, FAFPHM; Flavia

Cicuttini, PhD, FRACP; Marie-Louise Dick, MPH,

FRACGP; Mark Harris, MD, FRACGP; Paul Johnson,

PhD, FRACP; Jenepher Martin, MD, FRACS; Adrian

Mindel, MD, FRACP; Campbell Thompson, MD,

FRACP; Tim Usherwood, MD, FRACGP; Owen

Williamson, FRACS, GradDipClinEpi; John Wilson,

PhD, FRACP; Jane Young, PhD, FAFPHM; Jeffrey

Zajac, PhD, FRACP

Australasian Medical Publishing Co Pty Ltd

Advertising Manager: Peter Butterfield

Media Coordinators: Kendall Byron; Julie Chappell

The Medical Journal of Australia (MJA) is published on the 1st and 3rd Monday of each month by the Australasian Medical Publishing Company Proprietary Limited, Level 2, 26-32 Pyrmont Bridge Rd, Pyrmont, NSW 2009. ABN 20 000 005 854. Telephone: (02) 9562 6666. Fax: (02) 9562 6699.

E-mail: medjaust@ampco.com.au. The Journal is printed by Offset Alpine Printing Ltd, 42 Boorea St, Lidcombe, NSW 2141.

MJA on the Internet: <http://www.mja.com.au/>

None of the Australasian Medical Publishing Company Proprietary Limited, ABN 20 000 005 854, the Australian Medical Association Limited, or any of its servants and agents will have any liability in any way arising from information or advice that is contained in *The Medical Journal of Australia* (MJA). The statements or opinions that are expressed in the Journal reflect the views of the authors and do not represent the official policy of the Australian Medical Association unless this is so stated. Although all accepted advertising material is expected to conform to ethical and legal standards, such acceptance does not imply endorsement by the Journal. All literary matter in the Journal is covered by copyright, and must not be reproduced, stored in a retrieval system, or transmitted in any form by electronic or mechanical means, photocopying, or recording, without written permission.

Published in 2 volumes per year.

Annual Subscription Rates for 2005 (Payable in Advance) to:

AMPCo, Locked Bag 3030, Strawberry Hills, NSW 2012

Individual Subscriptions (includes 10% GST)

Australia: \$A319.00, Medical students (Australia only): \$A60.00

Overseas: \$A410.00

Indexes are published every 6 months and are available on request as part of the current subscription.

Single or back issues contact: AMPCo (02) 9562 6666.

Advice to Authors—

<http://www.mja.com.au/public/information/instruc.html>



28,516 circulation as at
30 September, 2004

ISSN 0025-729X